Pharmaceutical Approach of Nano- Particles as a Targeted Nasal-Brain Delivery System
DOI:
https://doi.org/10.31351/vol34iss4pp44-56Abstract
The first study reported for nasal brain drug delivery was in 1937. The uptake of nasal - brain drug delivery, has received a great deal of attention as a convenient, method for the systemic administration of drugs. Which are low less effective orally, and, only effective if administered by injection. Many well-known different pathways and routes for drug absorption via the nose are affected by various factors. Some of them are factors related to the natural physiology of the nose and mucociliary clearance, enzyme, blood flow in the nasal cavity, and diseases. The bio-fate of drugs instilled in nasal cavity, is mainly affected by the pharmaceutical and pharmacokinetic properties of the drugs Pharmaceutical nanoparticulate carriers, also known as nanomedicines, offer numerous benefits for delivering neurotherapeutics from the nose to the brain. Most types of nanocarriers have been extensively researched for this purpose, including nanoemulsions and solid-lipid nanoparticles (SLNs)., and nanosuspensions. However, there are multiple potential problems associated with the intranasal route of administration of nanocarriers, such as, toxicity and irritation of the nasal mucosa, stability of nanocarriers inside the nasal membranes, and possible degradation of enzymes during passage. In general, the adherence of the traditional formulation to the mucosal membrane of the nasal cavity can be enhanced by including synthetic polymers such as Eudragits, which are derived from acrylic and methacrylic acid. The destiny of nanocarriers is determined by their inherent physicochemical characteristics. For example, the characteristics that can be considered include the composition, particle size, surface charge, as well as surface hydrophobicity or hydrophilicity. Different experimental models were used in the published studies, like in vitro, in vivo and ex-vivo models, besides to cell culture and, cell line models. This quantitative analysis must be revealed as blood- brain drug ratio, besides to absolute, and relative bioavailability of the drug delivered by the brain Moreover, qualitative analysis should be recognized for most of nano particle’s morphology like optical imaging, brain histopathology, fluorescence microscope, and gamma scintigraph. In the following review article, aims are provided a detailed review of literature concerning direct nose-to-brain drug delivery.
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv. Rev. 2012;64:61
Harkema JR, Carey SA, Wagner JG. The nose revisited: a brief review of the comparative structure, function, and toxicological pathology of the nasal epithelium. Toxicol Pathol2006;34:252–69.4–28.
Akel H, Ismail R, Csoka I. Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer’s disease. EurJ . Pharm Biopharm 2020;148:38–53.
Watelet JB, Van Cauwenberge P. Applied anatomy and physiology of the nose and paranasal sinuses. Allergy 1999;54:14–25.
Illum L. Nasal delivery. The use of animal models to predict performance in man. J Drug Target 1996;3:427–42.
Sahin-Yilmaz A, Naclerio RM. Anatomy and physiology of the upper airway. Proc Am Thorac Soc Am Thorac Soc 2018:31–9.
Illum L. Is nose-to-brain transport of drugs in man a reality ?, J Pharm Pharmacol 2004;56:3.
Charlton ST, Davis SS, Illum L. Evaluation of bioadhesive polymers as delivery systems for nose to brain delivery: in vitro characterisation studies. J Control Release 2007;118:225–34.
Jones N. The nose and paranasal sinuses physiology and anatomy. Adv Drug Deliv Rev 2001;51:5–19.
Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 2012;64:614–28.
Lale A, Mason JDT, Jones NS. Mucociliary transport and its assessment. ClinOtolaryngol 1998;23:388–96.
Cole P. Physiology of the nose and paranasal sinuses. Clin Rev Allergy Immunol 1998;16:25–55.
Ga´spa´r R, Sztojkov-ivanov A, Ducza E, Ma´rkiA´ . Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine : preparation, characterization, and in vivo evaluation. Int J Pharm 2020.
Kristensson K. Microbes’ roadmap to neurons. Nat Rev Neurosci. 2011;12:345–57.
Eid HM, Elkomy MH, El Menshawe SF, Salem HF. Transfersomal nanoparticles for nose-to-brain delivery of ofloxacin for better management of bacterial meningitis: formulation, optimization by Box-Behnken design, characterization and in vivo pharmacokinetic study. J Drug Deliv Sci Technol 2019.
Kristensson K. Microbes’ roadmap to neurons. Nat Rev Neurosci 2011;12:345–57
Wolburg H, Wolburg-Buchholz K, Sam H, Horvat S, Deli MA, Mack AF. Epithelial and endothelial barriers in the olfactory region of the nasal cavity of the rat. Histochem Cell Biol 2008;130:127–40.
Scranton RA, Fletcher L, Sprague S, Jimenez DF, Digicaylioglu M. The rostral migratory stream plays a key role in intranasal delivery of drugs into the CNS. PLoS One 2011;6, e18711.
Iqbal R, Ahmed S, Jain GK, Vohora D. Design and development of letrozole nanoemulsion : a comparative evaluation of brain targeted nanoemulsion with free letrozole against status epilepticus and neurodegeneration in mice. Int J Pharm 2019;565:20–32.
Wang F, Yang Z, Liu M, Tao Y, Li Z, Wu Z, Gui S. Facile nose-to-brain delivery of rotigotine-loaded polymer micelles thermosensitive hydrogels: in vitro characterization and in vivo behavior study. Int J Pharm 2020;577:119046.
Wong YC, Zuo Z. Brain disposition and catalepsy after intranasal delivery of loxapine : role of metabolism in PK/PD of intranasal CNS drugs. Pharm Res 2013..
Dalpiaz A, Fogagnolo M, Ferraro L, Beggiato S, Hanuskova M, Maretti E, Sacchetti F, Leo E, Pavan B. Bile salt-coating modulates the macrophage uptake of nanocores constituted by a zidovudine prodrug and enhances its nose-to-brain delivery. Eur J Pharm Biopharm 2019;144:91–100.
Pandey A, Singh D, Dhas N, Tewari AK, Pathak K, Chatap V, Rathore KS, Mutalik S. Complex injectable: Development, delivery and advancements. Elsevier; 2020. p. 191–213.
Thorne RG, Pronk GJ, Padmanabhan V, Frey 2nd WH. Delivery of insulin-like growth factor-I to the brain and spinal cord along olfactory and
trigeminal pathways following intranasal administration. Neuroscience 2004;127(2):481–96.
Belgamwar AV, Khan SA, Yeole PG. Intranasal dolutegravir sodium loaded nanoparticles of hydroxypropyl-beta- cyclodextrin for brain delivery in Neuro-AIDS. J Drug Deliv Sci Technol 2019;52:1008–20.
Salade L, Wauthoz N, VermeerschM, Amighi K, Goole J. Chitosan-coated liposome dry-powder formulations loaded with ghrelin for nose-to-brain delivery. Eur J Pharm Biopharm 2018;129:257–66
Ahmad N, Ahmad R, Ahmad FJ, Ahmad W, Alam MA, Amir M, Ali A. Poloxamer-chitosan-based Naringenin nanoformulation used in brain targeting for the treatment of cerebral ischemia. Saudi J Biol Sci 2020;27:500–17.
Hamed HE, Hussein AA. Preparation, in vitro , e x-vivo evaluation of mirtazapine nanosuspension and nanoparticles incorporated in orodispersible tablets. Iraqi J Pharmaceutical Sci. 2020;29(1):62–75.
Pattni BS, Torchilin VP. Targeted drug delivery systems: strategies and challenges. In: Devarajan PV, Jain S, editors. Targeted drug delivery: Concepts and design. Springer; 2015. p. 3–38.
Ali AH, Abd-Alhammid SN. Enhancement of solubility and improvement of dissolution rate of atorvastatin calcium prepared as nano suspension. Iraqi J Pharm Sci. 2019;28(2):46–57.
Saba Abdulhadee Jabir, HalahTalal Sulaiman, preparation and characterization of lafutidine as oral release strip using different water soluble polymers, International Journal of Applied Pharmaceutics: Vol 10, Issue 5 (Sep-Oct), 2018
Dhas NL, Kudarha RR, Mehta TA. Intranasal delivery of nanotherapeutics/nanobiotherapeutics for the treatment of Alzheimer’s disease: a proficient approach. Crit Rev Ther Drug 2019;36:373–447.
Nasser ST, Ghareeb AAAMM. Design, Preparation and In-vitro Evaluation of Novel Ocular Antifungal Nanoemulsion Using Posaconazole as a Model Drug. Technology. 2021;11(3):1-7.
Sulaiman HT, Kassab HJ. Preparation and characterization of econazole nitrate inclusion complex for ocular delivery system. Int .J . App Pharm. 2018;10(3):175-81.
Pardeshi CV, Belgamwar VS, Surana SJ. Nanotechnology-mediated nose-to-brain drug delivery for neurodegenerative disorders. In: Rai M, Yadav A, editors. Nanobiotechnology in neurodegenerative diseases. Switzerland: Springer Nature; 2019. p. 163–75.
Khafagy E-S, Kamei N, Fujiwara Y, Okumura H, Yuasa T, et al. Systemic and brain delivery of leptin via intranasal coadministration with cellpenetrating peptides and its therapeutic potential for obesity. J Control Release 2020; 319:397–406.
TosM. Distribution of mucus producing elements in respiratory tract. Differences between upper and lower airways. Eur J Respir Dis 1983; 64:269–79.
Ribeiro E, Junior DO, Truzzi E, Ferraro L, Fogagnolo M, Pavan B, Beggiato S, Maretti E, Lima EM, Leo E, Dalpiaz A. Nasal administration of nanoencapsulated geraniol/ursodeoxycholic acid conjugate: towards a new approach for the management of Parkinson’s disease. J Control Release 2020; 321:540–52.
Ahmad N, Ahmad R, Ahmad FJ, Rub RA. Quantification and evaluation of glycyrrhizic acid-loaded surface decorated nanoparticles by UHPLC-MS/MS and used in the treatment of cerebral ischemia. Curr Pharm Anal. 2020;14:24–39.
Merkus FW, Verhoef JC, Schipper NG, Marttin E. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev 1998;29:13–38.
Wang F, Yang Z, Liu M, Tao Y, Li Z, Wu Z, Gui S. Facile nose-to-brain delivery of rotigotine-loaded polymer micelles thermosensitive hydrogels: in vitro characterization and in vivo behavior study. Int J Pharm 2020;577:119046.
Foo MY, Cheng YS, Su WC, Donovan MD. The influence of spray properties on intranasal deposition. J Aerosol Med 2007;20:495–508.
Alwan RM, Rajab NA., Nanosuspensions of Selexipag: Formulation, Characterization, and in vitro Evaluation , Iraqi Journal of Pharmaceutical Sciences (P-ISSN 1683-3597 E-ISSN 2521-3512). 2021;30(1):144-53.
Alaa A. Abdulqader*, Nawal A. Rajab, Preparation and characterization of Posaconazole as a Nano-micelles using d-α-Tocopheryl polyethylene glycol 1000 succinate , Iraqi J Pharm Sci, Vol.32, 2023
Hashim AA-J, Rajab NA. Anastrozole Loaded Nanostructured Lipid Carriers: Preparation and Evaluation. Iraqi Journal of Pharmaceutical Sciences , 2021 :30 (20) ,185-95.
Abdulqader AA, Rajab NA., Bioavailability study of Posaconazole in rats after oral Poloxamer P188 Nano-micelles and oral Posaconazole pure drug. Journal of Advanced Pharmacy Education & Research| Apr–Jun. 2023;13(2):141.
Sadoon N A, Ghareeb M M.Formulation and Characterization of Isradipineas Oral Nanoemulsion. Iraqi J Pharm Sci, Vol.29 (1) 2020.
Ghareeb MM, Neamah AJ. Formulation and characterization of nimodipinenanoemulsion as ampoule for oral route. International Journal of Pharmaceutical Sciences and Research. 2017;8(2):591.
Ahmad E, Lv Y, Zhu Q, Qi J, Dong X, Zhao W, Chen Z, Wu W, Lu Y. TAT modification facilitates nose-to-brain transport of intact mPEG-PDLLA micelles: evidence from aggregation-caused quenching probes. Appl Mater Today 2020;19:1–13.
Li J. Surface-modified PLGA nanoparticles for targeted drug delivery to neurons. 47. Louisiana State University; 2012 [Master’s Theses].
Mistry A, Glud SZ, Kjems J, Randel J, Howard KA, Stolnik S, Illum L. Effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium. J . Drug Target 2009;17:543–52.
Lungare S, Bowen J, Badhan R. Development and evaluation of a novel intranasal spray for the delivery of amantadine. J Pharm Sci 2016;105 (3):1209–20.
Chatterjee B. Nose to brain drug delivery: a recent update. J FormulSciBioavailab 2018;1(1):1–2.
Yoo J, Park C, Yi G, Lee D, Koo H. Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancer 2019;11:640.
Ducza E, Sztojkov-ivanov A, Ambrus R, Pallagi E. Development of meloxicam-human serum albumin nanoparticles for nose-to-brain delivery via application of a quality by design approach. Pharmaceutics 2020;12:97.
Liu H, Zhang W, Fang Y, Yang H, Tian L, Li K, Lai W, Bian L, Lin B, Liu X, Xi Z. Neurotoxicity of aluminum oxide nanoparticles and their mechanistic role in dopaminergic neuron injury involving p53-related pathways. J Hazard Mater 2020;392:122312.
Fox SH, Brotchie JM. The MPTP-lesioned non-human primate models of Parkinson’s disease. Past, present, and future. Prog Brain Res 2010;184:133–57.
Grow DA, McCarrey JR, Navara CS. Advantages of nonhuman primates as preclinical models for evaluating stem cell-based therapies for Parkinson’s disease. Stem Cell Res 2016;17(2):352–66.
Harris CM, Mendes F, Dragomir A, Doull IJM, Carvalho-Oliveira I, Bebok Z, Dormer RL. Assessment of CFTR localisation in native airway epithelial cells obtained by nasal brushing. J. Cyst Fibros 2004;3(Suppl. 2):43–8.
Kurti L, Gaspar R, Marki A, Ka´polna E, Bocsik A, Veszelka S, Szabo-Revesz P. In vitro and in vivo characterization of meloxicam nanoparticles designed for nasal administration. Eur J Pharm Sci 2013;50(1):86–92.
Chung EP, Cotter JD, Prakapenka AV, Cook RL, DiPerna DM, Sirianni RW. Targeting small molecule delivery to the brain and spinal cord via intranasal administration of rabies virus glycoprotein (RVG29)-modified PLGA nanoparticles. Molecules 2020;12:93.
KhosrowTayebati S, EjikeNwankwo I, Amenta F. Intranasal drug delivery to the central nervous system: present status and future outlook. Curr Pharm Des 2012;19(3):510–26.
Qin T, Yin Y, Wang X, Liu H, Lin J, Yu Q, Yang Q. Whole inactivated avian influenza H9N2 viruses induce nasal submucosal dendritic cells to sample luminal viruses via transepithelial dendrites and trigger subsequent DC maturation. Vaccine 2014;33(11):1382–92.
de Oliveira Junior ER, Truzzi E, Ferraro L, Fogagnolo M, Pavan B, Beggiato S, Rustichelli C, Maretti E, Lima EM, Leo E, Dalpiaz A. Nasal administration of nanoencapsulatedgeraniol/ursodeoxycholic acid conjugate: towards a new approach for the management of Parkinson’s disease. J Control Release 2020;10:540–52..
Zhang X, Huang W, Shao Q, Yang Y, Xu Z, Chen J, Zhang X, Ge X. Drp1, a potential therapeutic target for Parkinson’s disease, is involved in olfactory bulb pathological alteration in the Rotenone-induced rat model. ToxicolLett 2020;325:1–13.
Ahmad E, Lv Y, Zhu Q, Qi J, Dong X, Zhao W, Chen Z, Wu W, Lu Y. TAT modification facilitates nose-to-brain transport of intact mPEG-PDLLA micelles: evidence from aggregation-caused quenching probes. Appl Mater Today 2020;19:100556.
Bi CC, Wang AP, Chu YC, Liu S, Mu HJ, Liu WH, Li YX. Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment. Int J Nanomedicine 2016;11:6547–59.
Muntimadugu E, Dhommati R, Jain A, Challa VGS, Shaheen M, Khan W. Intranasal delivery of nanoparticle encapsulated tarenflurbil: a potential brain targeting strategy for Alzheimer’s disease. Eur J Pharm Sci 2016;92:224–34.
Al Asmari AK, Ullah Z, Tariq M, Fatani A. Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil. Drug Development Therapeutics 2016;10:205–15.
Kiparissides C, Vasileiadou A, Karageorgos F, Serpetsi S. A computational systems approach to rational design of nose-to-brain delivery of biopharmaceutics. Ind Eng Chem Res 2020;59:2548–65.
Reddy LH, Bazile D. Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: illustration with the case of taxane therapeutics. Adv Drug Deliv Rev 2014;71:34–57.
Takeuchi H, Imamura K, Ji B, Tsukita K, Enami T, Takao K, Miyakawa T, Hasegawa M, Sahara N, Iwata N, Inoue M, Hara H, Tabira T, Ono M, Trojanowski JQ, Lee VMY, Takahashi R, Suhara T, Higuchi M, Inoue H. Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice. npj Vaccines 2020;5(1):2–11.
Panteli_c I, Savic S, Ilic T, Todosijevi_c M, Savic M, Savic S. From physicochemically stable nanocarriers to targeted delivery: in vivo pharmacokinetic, pharmacodynamic and biodistribution studies. In: Grumezesku EM, editor. Nanoscale fabrication, optimization, scale-up and biological aspects of pharmaceutical nanotechnology. Amsterdam: Elsevier; 2017. p. 301–33..
Shakeri S, Ashrafizadeh M, Zarrabi A, Roghanian R, Afshar EG, Pardakhty A, et al. Multifunctional polymeric nanoplatforms for brain diseases diagnosis, therapy and theranostics. Biomedicines 2020;8(1):13.
Lu W, Jiang W, Chen J, Yin M, Wang Z, Jiang X. Modulation of brain delivery and copulation by intranasal apomorphine hydrochloride. Int J Pharm 2008;349(1–2):196–205.
Upadhaya PG, Pulakkat S, Patravale VB. Nose-to-brain delivery: exploring newer domains for glioblastoma multiforme management. Drug DelivTransl Res 2020. [48] O’Connor D. World
Durand E, Petit O, Tremblay L, Zimmer C, Sgambato-Faure V, Chassain C, Durif F. Social behavioral changes in MPTP-treated monkey model of Parkinson’s disease. Front Behavior Neuroscinces2015;9(42):1–19.
Xiong Y, Yu J. Modeling Parkinson’s disease in Drosophila: what have we learned for dominant traits? Front Neural 2018;9:228.
Stefanis L. a-Synuclein in Parkinson’s disease. Cold Spring HarbPerspect Med 2012;2(2).
Agrawal M, Saraf S, Saraf S, Dubey SK, Puri A, Patel RJ, Ajazuddin, Ravichandiran V, Murty US, Alexander A. Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting. J Control Release 2020;321:372–415.
Kozlovskaya L, Abou-Kaoud M, Stepensky D. Quantitative analysis of drug delivery to the brain via nasal route. J Control Release 2014;189 (10):133–40.
Erdoa F, Borsa Luca A, Farkasa D, Bajzaa A, Gizurarson S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull 2018;143:155–70.
Pires PC, Santos AO. Nanosystems in nose-to-brain drug delivery: a review of non-clinical brain targeting studies. J Control Release 2018;28 (270):89–100.
Cremers T, Gunnar Flik H, Rollema F, Robert E, Stratford J. Development of a rat plasma and brain extracellular fluid pharmacokinetic model for bupropion and hydroxybupropion based on microdialysis sampling, and application to predict human brain concentrations. Drug MetabDispos 2016;44:624–33.
Pardeshi CV, Belgamwar VS. N,N,N-trimethyl chitosan modified flaxseed oil based mucoadhesiveneuronanoemulsions for direct nose to brain drug delivery. Int J BiolMacromol 2018;120(Pt B):2560–71.
Abdel Hady M, Sayed OM, Akl MA. Brain uptake and accumulation of new levofloxacin-doxycycline combination through the use of solid lipid nanoparticles: formulation; optimization and in-vivo evaluation. Colloids Surf B: Biointerfaces 2020;193:111076.
Carvalho LA, Teng J, Fleming RL, Tabet EI, Zinter M, de Melo Reis RA, Tannous BA. Olfactory ensheathing cells: a Trojan horse for glioma gene therapy. J Natl Cancer Inst 2019;111:283–91.
Ahmad N, Ahmad R, Ahmad FJ, Ahmad W, Alam MA, Amir M, Ali A. Poloxamer-chitosan-based naringeninnanoformulation used in brain targeting for the treatment of cerebral ischemia. Saudi J Biol Sci 2020;27:500–17.
Abegg D, Gasparini G, Hoch DG. Strained cyclic disulfides enable cellular uptake by reacting with the transferrin receptor. J Am. Chem .Society 2016;139:231–8.
Dhaliwal HK, Fan Y, Kim J, Amiji MM. Intranasal delivery and transfection of mRNA therapeutics in the brain using cationic liposomes. Mol Pharm 2020.
Bors LA, Bajza A, Mandoki M, Tasi BJ, Cserey G, Imre T, Szabo P, Erdo F. Modulation of nose-to-brain delivery of a P-glycoprotein (MDR1) substrate model drug (quinidine) in rats. Brain Res Bull 2020;160:65–73.
Feigin VL, Vos T, Nichols E, Owolabi MO, Carroll WM, Dichgans M, Deuschl G, Parmar P, Brainin M, Murray C. The global burden of neurological disorders: translating evidence into policy. Lancet Neurol 2020;19(3):255–65.
Passoni A, Favagrossa M, Colombo L, Bagnati R, Gobbi M, Diomede L, Birolini G, Paolo ED, Valenza M, Cattaneo E, Salmona M. Efficacy of cholesterol nose-to-brain delivery for brain targeting in Huntington’s disease. ACS ChemNeurosci 2020;11(3):367–72.
Amit C, Viral P, Prakash SO, Atul G. Application and functional characterization of kollicoatsmartseal 30D as a solid dispersion carrier for improving solubility. Asian J Pharm 2020;14:1–9.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
